No Data
Bai Ke Biological (688276.SH): Application for clinical trials of type II herpes simplex virus mRNA vaccine has been approved.
On December 20, Gelonghui announced that Baike Biomedical (688276.SH) recently received the "Notice of Approval for Clinical Trials of Pharmaceuticals" issued by the National Medical Products Administration, agreeing to conduct clinical trials for the prevention of genital herpes caused by type II herpes simplex virus infection. Genital herpes caused by type II herpes simplex virus infection is a contagious disease primarily spread through sexual activity, which is easily transmitted, recurrent, and lacks effective curative measures, leading to a serious public health issue. To prevent the occurrence of genital herpes, multiple Biomedical companies have been continuously working on the research and development of herpes simplex virus vaccines.
Baikexing Biological (688276.SH) no longer recognizes Zhu Changlin as a core technical personnel.
Baike Biological (688276.SH) released an announcement that the company, based on its Global Strategy development plan, comprehensively considers the company's research and development projects...
Baikexue Bio (688276.SH): Elect Li Xiufeng as Director.
Gelonghui reported on December 10 that Baike Biotechnology (688276.SH) announced that it will hold the first meeting of the sixth Board of Directors on December 10, 2024, to review and approve the proposal regarding the election of the chairman of the sixth Board of Directors. The Board of Directors agrees to elect Mr. Li Xiufeng as the chairman of the sixth Board of Directors, with his term of office starting from the date of approval by this Board of Directors until the expiration of the sixth Board of Directors.
Changchun BCHT Biotechnology (SHSE:688276) Has A Pretty Healthy Balance Sheet
Baige Biotechnology (688276.SH) shareholder Wei Xueling's shareholding has decreased to 5%.
Baike Biotechnology (688276.SH) announced that shareholder Wei Xuening's shareholding ratio decreased from 8.7225%...
Public Companies Who Hold 41% of Changchun BCHT Biotechnology Co. (SHSE:688276) Gained 4.1%, Insiders Profited as Well
Investors Still Waiting For A Pull Back In Changchun BCHT Biotechnology Co. (SHSE:688276)
